来自官方财务报表的收入、利润与现金流历史。
辉瑞公司在美国和国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司分为三个部门：生物制药部门、PC1 部门和辉瑞 Ignite 部门。该公司提供内科产品，包括Eliquis品牌下的心血管代谢疾病产品； Nurtec ODT/Vydura 和 Zavzpret 品牌的偏头痛产品； Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba 品牌的疫苗；和 Paxlovid 用于治疗 COVID-19。它还提供炎症和免疫学产品，例如 Xeljanz、Enbrel、Cibinqo、Litfulo、Eucrisa 和 Velsipity；用于治疗领域的罕见疾病产品，包括 Vyndaqel 家族、Genotropin、BeneFIX、Xyntha、Somavert、Ngenla 和 Hympavzi 品牌下的淀粉样变性、血友病和内分泌疾病； Zavicefta、Octagam 和 Panzyga 品牌下的抗感染和免疫球蛋白药物。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $63.7B | $62.6B | $63.6B | $59.6B | $100.3B | $81.3B | $41.7B | $41.2B | $53.6B | $52.5B | $52.8B | $48.9B | $49.6B | $51.6B | $54.7B | $61.0B | $67.1B | $50.0B | $48.3B | $48.4B | $48.4B |
| 毛利 | $45.4B | $44.0B | $41.8B | $30.3B | $62.1B | $46.9B | $29.9B | $28.5B | $37.6B | $36.8B | $36.9B | $35.7B | $36.3B | $37.6B | $40.0B | $43.9B | $46.3B | $38.4B | $38.3B | $36.7B | $37.9B |
| 毛利率% | 71.3% | 70.3% | 65.8% | 50.9% | 61.9% | 57.7% | 71.7% | 69.3% | 70.2% | 70.0% | 69.8% | 73.1% | 73.2% | 73.0% | 73.2% | 71.9% | 69.1% | 76.8% | 79.2% | 75.8% | 78.3% |
| 营业利润（EBIT） | $16.0B | $15.4B | $16.5B | $5.3B | $37.5B | $20.8B | $9.1B | $7.5B | $15.3B | $14.4B | $14.3B | $13.3B | $14.0B | $16.9B | $18.0B | $18.4B | $17.7B | $16.0B | $16.6B | $13.9B | $15.1B |
| 营业利润率% | 25.1% | 24.7% | 25.9% | 8.9% | 37.4% | 25.6% | 21.8% | 18.2% | 28.5% | 27.4% | 27.0% | 27.2% | 28.3% | 32.7% | 33.0% | 30.1% | 26.4% | 32.0% | 34.4% | 28.7% | 31.2% |
| 净利 | $4.3B | $7.8B | $8.0B | $2.1B | $31.4B | $22.1B | $9.2B | $16.3B | $11.2B | $21.3B | $7.2B | $7.0B | $9.1B | $11.6B | $9.8B | $8.7B | $8.3B | $8.6B | $8.0B | $8.2B | $11.0B |
| 净利润率 % | 6.8% | 12.4% | 12.6% | 3.6% | 31.3% | 27.3% | 22.0% | 39.5% | 20.8% | 40.6% | 13.7% | 14.3% | 18.3% | 22.6% | 17.9% | 14.3% | 12.3% | 17.3% | 16.6% | 17.0% | 22.8% |
| EBITDA | $12.6B | $15.1B | $18.1B | $9.6B | $41.0B | $30.8B | $13.2B | $18.9B | $19.6B | $19.8B | $15.3B | $15.3B | $19.1B | $23.5B | $20.4B | $22.2B | $19.6B | $16.8B | $15.3B | $14.9B | $18.8B |
| 每股收益（EPS） | $0.76 | $1.37 | $1.41 | $0.37 | $5.47 | $3.88 | $1.63 | $2.87 | $1.87 | $17.58 | $5.86 | $5.57 | $1.32 | $1.69 | $1.30 | $1.11 | $1.02 | $1.23 | $1.19 | $1.18 | $1.52 |
| 已发行股数 (M) | 5,699M | 5,686M | 5,700M | 5,709M | 5,733M | 5,708M | 5,632M | 5,675M | 5,977M | 1,212M | 1,232M | 1,251M | — | 6,895M | 7,508M | 7,870M | 8,074M | 7,045M | 6,750M | 6,939M | 7,274M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PFE 交互式查看器。 /companies/us/PFE
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms